Quantcast

Latest Novelos Therapeutics Inc. Stories

2011-06-13 07:30:00

MADISON, Wis., June 13, 2011 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that Harry S. Palmin, President and CEO of Novelos, will present at the 5th Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on Thursday, June 16, 2011, at 11:30 a.m. Eastern time. The webcast of the Novelos presentation may be accessed at www.novelos.com The webcast...

2010-06-29 07:31:00

SAINT PETERSBURG, June 29, 2010 /PRNewswire/ -- The Company VAM is the developer of product Glutoxim(R) registered in Russia in 1998, registration No. P N002010/01. We possess significant knowledge and experience in manufacturing of this product as well as in the clinical development application of Glutoxim(R). In accordance with an Agreement dated June 20, 2000, the company VAM diligently and successfully transferred all of the "know-how", manufacturing and quality assurance information...

2008-11-04 09:00:30

Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Harry S. Palmin, President and CEO of Novelos, will present at the Rodman & Renshaw 10th Annual Healthcare Conference on Monday, November 10, 2008. Mr. Palmin is scheduled to present at 11:10am EST in Kennedy I, 4th floor. The event will be held at the New York Palace Hotel, 455 Madison Avenue, New York, NY. A live...

2008-09-10 09:00:48

Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Harry S. Palmin, President and CEO of Novelos, will present at Merriman Curhan Ford's 5th annual Investor Summit on September 15, 2008. Mr. Palmin is scheduled to present at 8am PDT (11am EDT) in Track 1 - California Room. Mr. Palmin will also participate in a panel discussion "What's Next on the Horizon in Biotech?" at 1:45pm...

2008-08-18 09:00:16

Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that it received $3 million from the sale of 4,615,384 shares of its common stock at $0.65 per share to two accredited investors. The shares of common stock were issued in a private placement transaction under Regulation D of the Securities Act of 1933 and have not been registered under the Securities Act of 1933, as amended, or any...

2008-08-11 09:01:40

Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Harry S. Palmin, President and CEO of Novelos, will present at the Noble Financial 4th Annual Equity Conference on Monday, August 18, 2008. Mr. Palmin is scheduled to present at 11am PDT (2pm EDT) at the Interceptor Room. The event will be held at the Lowes Lake Las Vegas Resort, Nevada. A live webcast of Mr. Palmin's...

2008-06-30 09:03:37

Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos was issued U.S. Pat. No. 7,371,411 by the U.S. Patent and Trademark Office extending the composition and method of use claims relating to NOV-002, Novelos' lead compound in an ongoing pivotal Phase 3 trial for non-small cell lung cancer under a Special Protocol Assessment (SPA) and Fast Track. NOV-002 has also demonstrated...

2008-06-16 09:01:19

Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos' peer reviewed article, based on the collaboration with Dr. Kenneth Tew and Dr. Danyelle Townsend of the Medical University of South Carolina (MUSC), has been published in Expert Opinion on Investigational Drugs (Volume 17, Issue 7, pages 1075-1083, 2008). This article describes clinical results as well as findings in...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.